Pneuma Respiratory, a leader in inhaled respiratory therapeutics, today announced the results of a groundbreaking study examining the aerosol composition of various nicotine delivery devices. The study highlights the absence of concerning heavy metals and organic compounds in Pneuma’s innovative, non-heated reduced-risk nicotine delivery system, reinforcing the company’s scientific leadership and commitment to harm reduction.

This study was performed to compare the amounts of concerning compounds in the emissions of several inhaled nicotine products. The compounds of interest included heavy metals (chromium, iron, nickel, copper, zinc, arsenic, cadmium, tin, silver, lead, beryllium, cobalt, selenium, and vanadium) and organic compounds (acetaldehyde, acrolein, butyraldehyde, crotonaldehyde, diacetyl, formaldehyde, furfural, pentanedione, acrylonitrile, and benzene).

Advancing inhaled respiratory therapeutics through innovative aerosol technology, we’re focused on bringing transformative solutions to market, starting with reduced-risk nicotine delivery and expanding into treatments for conditions like COPD and lung cancer. Our proprietary aerosol generation technology features non-heated, water-based solutions and ultra-fine droplet precision, achieving over 90% aerosol delivery to the lungs.